January 2022
Molnupiravir: Enzyme Recycling Information for M4ALL's Two-step Enzymatic Process
Medicines for All
December 2021
Toward a Practical, Nonenzymatic Process for Investigational COVID-19 Antiviral Molnupiravir from Cytidine: Supply-Centered Synthesis.
Vijayagopal Gopalsamuthiram, Appasaheb L. Kadam, Jeffrey K. Noble, David R. Snead, Corshai Williams, Timothy F. Jamison, Chris Senanayake, Ajay K. Yadaw, Sarabindu Roy, Gopal Sirasani, B. Frank Gupton, Justina Burns, Daniel W. Cook, Rodger W. Stringham, Saeed Ahmad, and Rudy Krack
October 2021
Engineering a Cytidine Aminotransferase for Biocatalytic Production of the Covid-19 Antiviral Molnupiravir
Ashleigh J. Burke, William R. Birmingham, Ying Zhuo, Bruna Zucoloto da Costa, Rebecca Crawshaw, Thomas W. Thorpe, Ian Rowles, James Finnigan, Carl Young, Simon J. Charnock, Sarah L. Lovelock, Nicholas J. Turner, and Anthony P. Green
July 2021
Toward a Practical, Two-Step Process for Molnupiravir: Direct Hydroxamination of Cytidine Followed by Selective Esterification
Dinesh J. Paymode, N. Vasudevan, Saeed Ahmad, Appasaheb L. Kadam, Flavio S.P. Cardoso, Justina M. Burns, Daniel W. Cook, Rodger W. Stringham, and David R. Snead
April 2021
Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine
Grace P. Ahlqvist, Catherine P. McGeough, Chris Senanayake, Joseph D. Armstrong, Ajay Yadaw, Sarabindu Roy, Saeed Ahmad, David R. Snead, And Timothy F. Jamison
October 2020
A concise route to MK-4482 (EIDD-2801) from cytidine
N. Vasudevan, Grace P. Ahlqvist, Catherine P. McGeough, Dinesh J. Paymode, Flavio S. P. Cardoso, Tobias Lucas, Jule-Phillip Dietz, Till Opatz, Timothy F Jamison, Frank B. Gupton and David R. Snead.
October 2020
A High-Yielding Synthesis of EIDD-2801 from Uridine
Alexander Steiner, Desiree Znidar, Sándor B. Ötvös, David R. Snead, Doris Dallinger, and C. Oliver Kappe
May 29, 2020
An Efficient Synthesis of Tenofovir (PMPA): A Key Intermediate Leading to Tenofovir-Based HIV Medicines
Brenden P. Derstine, John W. Tomlin, Cheryl L. Peck, Jule-Phillip Dietz, Brenden T. Herrera, Flavio S. P. Cardoso, Dinesh J. Paymode, Andrew C. Yue, Anthony J. Arduengo III, Till Opatz, David R. Snead, Rodger W. Stringham, D. Tyler McQuade*, and B. Frank Gupton*
March 2020
Supply Centered Synthesis to Current Late-State Intermediate: (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl 5-hydroxy-1,3-oxathiolane-2-carboxylate
Medicines for All
June 2019
Continuous synthesis of the pyridone in route to dolutegravir
Medicines for All
April 2019
Synthesis of 5-Fluorocytosine Using 2-Cyano-2-fluoroethenolate as a Key Intermediate
Jule-Philipp Dietz, Brenden P. Derstine, Dorota Ferenc, Evan T. Crawford, Anthony J. Arduengo III, B. Frank Gupton, D. Tyler McQuade, and Till Opatz
March 2019
A Holistic Approach to Streamlining Pharmaceutical Processes: A Conversation
B. Frank Gupton and D. Tyler McQuade
January 2019
5-fluorocytosine
Medicines for All
January 2019
Process Design and Optimization for the Continuous Manufacturing of Nevirapine, an Active Pharmaceutical Ingredient for HIV Treatment
Samir Diab, D. Tyler McQuade, B. Frank Gupton, and Dimitrios I. Gerogiorgis
May 2018
7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir
Robert E. Ziegler, Bimbisar K. Desai, Jo-Ann Jee, B. Frank Gupton, Thomas D. Roper, and Timothy F. Jamison
May 2017
Increasing global access to the high-volume HIV drug nevirapine through process intensification
Jenson Verghese, Caleb J. Kong, Daniel Rivalti, Eric C. Yu, Rudy Krack, Jesus Alcázar, Julie B. Manley, D. Tyler McQuade, Saeed Ahmad, Katherine Belecki and B. Frank Gupton
May 2015
The Medicines for All Initiative: the nevirapine process optimization
Medicines for All
November 2015
The Medicines for All Initiative: continuous synthesis of nevirapine and reaction monitoring with online PAT
Medicines for All